Innovative Immunotherapy AVM0703 presents a novel mechanism that mobilizes endogenous gamma delta TCR+ and invariant TCR+ bispecific NK-like cells, offering a potentially first-in-class immunotherapy for no-option cancer, autoimmunity, and infectious diseases. This distinctive mechanism creates licensing and co-development opportunities with oncology, autoimmune, and infectious disease players looking to expand their immunotherapy portfolios. Target collaboration options include in-licensing the asset, co-development deals, or milestone-driven partnerships with large pharma or mid-size biotech.

SBIR Momentum Two $2M NCI SBIR grants (recently awarded Jan 2026 and earlier) bring non-dilutive funding to roughly $6.4M government support to date, de-risking early-stage development and enabling phase planning. This creates an attractive entry point for partners to co-fund development, potentially enabling accelerated timelines and shared risk with AVM.

Strategic Partnerships Active business development as evidenced by the 2024 LOI with Xtacy Therapeutics and ongoing outreach toward pharma partners indicate a clear path for licensing or co-development. Opportunities exist to extend similar partnerships with oncology, immunology, and biotech companies, accelerating clinical and commercial milestones and expanding manufacturing, distribution, and regulatory support.

Commercial Readiness Leadership investments in commercial roles (CCO and CFO appointed in 2022-2024, COO hired in 2020) show formal market readiness and go-to-market planning. This suggests readiness to negotiate out-licensing or joint commercialization agreements and to support partner-driven clinical development and scale-up.

Target Markets Focused indications include NHL, solid tumors, and autoimmune disorders, with potential expansion into infectious diseases. This aligns AVM’s platform with large, well-funded therapeutic areas and creates multiple partnering tracks across oncology, autoimmunity, and infectious disease franchises. The Seattle base and high-profile scientific advisory board may help engage US-based pharma and government grant-backed collaborations.